Provision of breast cancer care and survival in Germany – results from a population-based high resolution study from Saarland

Table 5 Five year relative survival and relative excess risk of death of female breast cancer patients by tumor characteristics, systemic treatment and age

Patient/tumor characteristics	Treatment	Provision	N	RS^a	SE	RER^b	95% CI	p-value
Nodal positive tumor, ER + or PgR+	Chemotherapy + antiestrogen treatment	yes	781	99.0	3.7	REF
		no	506	86.2	3.1	1.45	0.78-2.68	0.239
Nodal positive tumor, ER + or PgR+, age 15–69 years	Chemotherapy + antiestrogen treatment	yes	701	92.0	1.8
		no	264	88.3	3.0
Nodal positive tumor, ER + or PgR+, age > =70 years	Chemotherapy + antiestrogen treatment	yes	80	95.0	8.9
		no	242	83.5	5.5
Nodal positive tumor, ER- and PgR-	Chemotherapy	yes	238	54.3	6.3	REF
		no	30	28.5	9.7	2.89	1.46-5.71	0.002
Nodal negative tumor, ER- and PgR-	Chemotherapy	yes	310	94.9	5.5	REF
		no	104	83.9	6.2	0.80	0.20-3.18	0.751
ER + or PgR+	Antiestrogen treatment	yes	3663	97.1	1.3	REF
		no	536	85.6	3.8	1.75	0.99-3.07	0.053
ER + or PgR+, age 15–69 years	Antiestrogen treatment	yes	2664	96.8	0.7
		no	401	89.4	2.4
ER + or PgR+, age > =70 years	Antiestrogen treatment	yes	999	96.2	2.5
		no	135	81.8	7.4
HER2/neu positive tumor	Targeted therapy	yes	198	89.3	9.5	REF
		no	509	84.4	4.1	2.17	0.91-5.14	0.080

Five year relative survival and relative excess risk of death of female breast cancer patients (ICD-10: C50) from Saarland estimated for calendar period 2005–2009 by tumor characteristics, systemic treatment and age. N: number of patients contributing survival experience; RS: point estimate of 5-year relative survival; SE: standard error of RS; RER: relative excess risk (of death); CI: confidence interval; a) except for age group-specific survival, age standardized estimates were derived using the ICSS weights; b) adjusted for age (15–49, 50–69, > = 70 years), tumor size (<5 cm (T1/T2), > = 5 cm (T3/T4)), lymph node involvement (negative, N1, N2/N3), histologic grade (G1/G2, G3/G4), hormone receptor status (ER + or PgR+, ER- and PgR-) and HER2/neu expression (positive, negative); including patients with microscopically verified tumors and available information on age, T, N, histologic grade, hormone receptor status, HER2/neu expression and provision of the respective systemic treatment; patients presenting with distant metastases or DCO notified tumors were excluded.

ISSN: 1471-2407